API
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [HEALTH]

2 clusters · 2 sources · 9 days · First seen · Last updated

Poland medical therapy access challenges

Overview

Patients in Poland face significant barriers to accessing advanced medical therapies for neurological conditions. For myasthenia gravis, despite the expansion of the B. 157 drug program to include three modern therapies in July 2024, many severely ill patients remain unable to benefit due to financial constraints, restrictive qualification criteria, and a lack of authorized medical centers.

Similarly, chronic migraine patients face limitations within the B. 133 drug program, which currently serves only a small fraction of the estimated 750,000 people suffering from the condition. Experts have suggested pharmacy reimbursement as a solution to improve access, but the Agency for Health Technology Assessment and Tariff System (AOTMiT) recently advised against the pharmacy reimbursement of Aquipta for adult chronic migraine prevention. The agency cited high costs and potential monitoring difficulties, projecting significant increases in National Health Fund spending.

Entities

Poland · Agency for Health Technology Assessment and Tariff System · Sylwia Łukomska · Agency for Health Technology Assessment and Tariffication · Alina Kułakowska

Timeline

  1. [HEALTH] 2 sources
    Poland: Migraine patients face barriers to modern treatment

    Migraine patients in Poland face significant treatment barriers as experts call for expanded reimbursement despite AOTMiT's recommendation against funding the drug Aquipta due to high costs.

  2. [HEALTH] 2 sources
    Access to advanced therapies remains a challenge for patients in Poland

    Patients with myasthenia gravis in Poland face limited access to new therapies due to financial constraints, restrictive qualification criteria, and a lack of specialized medical centers.

Sources

opieka.farm · rynekzdrowia.pl